000047656 000__ 03698cam\a22004575i\4500
000047656 001__ 47656
000047656 003__ SzGeWIPO
000047656 005__ 20230322180815.0
000047656 006__ m\\\\e\\\d\\\\\\\\
000047656 007__ cr bn |||m|||a
000047656 008__ 230320s2022\\\\enk\\\\\\\\\\\001\0\eng\d
000047656 020__ $$a9781803927381$$qe-book 
000047656 020__ $$z9781803927374$$qhardback 
000047656 035__ $$aeep9781803927381
000047656 035__ $$a(OCoLC)1373643446
000047656 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000047656 041__ $$aeng
000047656 042__ $$apcc
000047656 043__ $$ae------
000047656 08204 $$a346$$220
000047656 1001_ $$aKlinge, Ulla Callesen,$$eauthor
000047656 24510 $$aPharmaceutical Patents under the SPC Regulation.
000047656 264_1 $$a[Northampton, England] :$$bEdward Elgar Publishing Ltd.,$$c2022.
000047656 300__ $$a286 pages.
000047656 336__ $$atext$$btxt$$2rdacontent
000047656 337__ $$aunmediated$$bn$$2rdamedia
000047656 338__ $$avolume$$bnc$$2rdacarrier
000047656 500__ $$aIncludes index.
000047656 5050_ $$aPreface -- Part I: Introduction and Context -- 1. Introduction to Pharmaceutical Patents under the SPC Regulation -- 2. The Pharmaceutical Industry and the Surrounding Legal and Economic Environment -- Part II: Legal Analysis of the SPC Regulation As It Is -- 3. Background and Purpose of the SPC System -- 4. Definition of “Product” and “Medicinal Product” -- 5. Eligibility for Protection of (Medicinal) Products under the SPC System -- 6. Conditions for Obtaining a Certificate (Art. 3) -- 7. Subject Matter of Protection (Art. 4) and Effects of the Certificate (Art. 5) -- 8. Conclusion on the Law as it is -- Part III: Legal Analysis of the SPC Regulation With Regard To Modern Pharmaceutical Innovation -- 9. SPC protection for biotechnological medicinal products -- 10. Secondary innovation -- Part IV: General Findings and Future Proposals -- 11. General Findings and Future Proposals Bibliography Index
000047656 520__ $$aWritten by an experienced European Patent Attorney and scholar, this book sets out in detail the framework for protection of pharmaceutical innovation under the SPC Regulation. With a focus on both biotechnological innovation and secondary innovation, and through extensive reference to the case law, Ulla Klinge surveys the court’s evolving interpretation of legal and technical eligibility for this extended term of protection. This book provides clear and pragmatic tools to reflect and guide future practice, while offering key explanations and insights as to why and how technological developments challenge the legal SPC framework.  Key Features:  • Broad, practitioner-oriented approach offers a useful source of reference alongside practical guidance • Analysis of SPC case law in light of developments in pharmaceutical technology, including both legal and technical aspects of the cases • Examination of the lack of clarity in interpretation of the legislation and how this might be exploited by stakeholders  Pharmaceutical Patents under the SPC Regulation is an indispensable practical resource for patent law practitioners, including patent attorneys and attorneys-at-law in the SPC field. It will also prove useful to national patent authorities, legislators, and academics working at the intersection between pharmaceuticals and legal research.$$cProvided by publisher.
000047656 588__ $$aDescription based on print record.
000047656 650_4 $$aLaw$$xIntellectual property law.
000047656 650_4 $$aLaw$$xBiotechnology and pharmaceuticals.
000047656 650_4 $$aEuropean law.
000047656 650_0 $$aPatents.
000047656 650_0 $$aIntellectual property.
000047656 655_0 $$aElectronic Books.
000047656 830_0 $$aElgar Intellectual Property Law and Practice Series
000047656 85640 $$uhttps://www.elgaronline.com/display/book/9781803927381/9781803927381.xml$$yView eBook
000047656 904__ $$aBook
000047656 980__ $$aOS